Lombard Odier Asset Management (Switzerland)’s Intellia Therapeutics NTLA Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-79,298	Closed	-$2.96M	–	308
2023 Q1	$2.96M	Buy	79,298 +18,294	+30%	+$717K	0.26%	92
2022 Q4	$2.13M	Hold	61,004	–	–	0.17%	117
2022 Q3	$3.41M	Sell	61,004 -4,312	-7%	-$267K	0.29%	80
2022 Q2	$3.38M	Sell	65,316 -13,773	-17%	-$699K	0.29%	84
2022 Q1	$5.75M	Sell	79,089 -34,222	-30%	-$2.9M	0.45%	60
2021 Q4	$13.4M	Sell	113,311 -35,495	-24%	-$4.45M	0.86%	45
2021 Q3	$20M	Sell	148,806 -6,395	-4%	-$968K	1.24%	38
2021 Q2	$25.1M	Sell	155,201 -127,752	-45%	-$9.95M	1.27%	26
2021 Q1	$22.7M	Buy	+282,953	New	+$19M	1.51%	21

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s NTLA Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 79,298 shares — an estimated $2.96M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in NTLA in Q1 2021 and held it in 9 quarters. The position peaked at $25.1M in Q2 2021. 291 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 79,298 Intellia Therapeutics shares in Q2 2023, an estimated $2.96M.
Lombard Odier Asset Management (Switzerland) first reported a position in Intellia Therapeutics in Q1 2021 and held it in 9 quarters.
Lombard Odier Asset Management (Switzerland)'s Intellia Therapeutics position peaked at $25.1M in Q2 2021.
291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.